Maximizing Prognostic Benefit: Risk-adaptive Approaches in Multiple Myeloma
Release Date: September 20, 2016
Expiration Date: September 20, 2017
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
In past years, several risk stratification models have been developed for prognosticating patients with multiple myeloma (MM). Recent updates and published consensus to the risk stratification process has led to recommended changes within current practice. Dr. Evangelos Terpos offers clinical expert recommendations concerning risk-adaptive therapeutic strategies in patients with MM, emphasizing how determination of prognosis is a critical component in identifying treatments specific for an individual patient’s unique risk level. Dr. Terpos also discusses clinical pearls for incorporating risk-adaptive approaches in a busy practice setting.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Describe risk-adaptive therapy in multiple myeloma
- Summarize how identification of prognosis impacts choice of therapeutic strategy in patients with multiple myeloma
Maximizing Prognostic Benefit: Risk-adaptive Approaches in Multiple Myeloma – Evangelos Terpos, MD, PhD
Instructions for Participation and Credit
This activity is eligible for credit through September 20, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Evangelos Terpos, MD, PhD
Associate Professor of Hematology
Department of Clinical Therapeutics
University of Athens, School of Medicine
Dr. Evangelos Terpos is an Associate Professor of Hematology in the Department of Clinical Therapeutics, University of Athens, School of Medicine in Greece, and has been appointed as Honorary Senior Lecturer in the Department of Haematology, Faculty of Medicine Imperial College London, UK.
Dr. Terpos is co-chair of the Bone Subgroup of the International Myeloma Working Group and the Guideline Subgroup of the European Myeloma Network. He has participated in multiple myeloma (MM) clinical trials with novel antimyeloma agents and has lectured nationally and internationally on cancer-induced bone disease. Dr. Terpos has reviewed scientific papers in more than 50 medical journals, as well as abstracts for EHA and ASH meetings. In addition, he is on the editorial board of Haematologica. His main research interest is the biology of plasma cell dyscrasias, especially the biology of bone disease in MM. In more than 350 papers in peer-reviewed journals, Dr. Terpos has reported the significant role of RANKL and osteoprotegerin axis, CCL-3 (MIP-1α), Wnt and TGF-beta signaling in myeloma bone disease and cell growth. He has studied the predictive value of markers of bone remodeling and osteoclast function in myeloma progression and patients’ survival, and has evaluated the effect of bisphosphonates and different anti-myeloma therapies on bone metabolism. In addition, he has studied the biology and prevalence of osteonecrosis of the jaw in myeloma patients who receive bisphosphonates. Dr. Terpos also works on the role of modern imaging for MM, angiogenesis in MM and Waldenström’s macroglobulinemia, and renal impairment in MM.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-079-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Evangelos Terpos has received honoraria related to formal advisory activities from Amgen Inc., Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology, and the development of educational materials from Amgen and Takeda. He has received consultant fees from Amgen, Celgene Corporation, Janssen, Novartis, and Takeda, as well as grant support related to research activities from Amgen and Janssen.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.